HIVHEPCure 2016 – Presentations

  Session 1: Introduction
Chair: F. Zoulim & S. Fung
 
Current status of HBV Therapy
Dr. P. Lampertico, University of Milan, Italy
 
Why do we need new treatments and what is our definition of cure?
Dr. H. Janssen, Toronto Centre for Liver Disease, Canada
  Session 2: New Treatment: Virological Approach
Chair: S. Locarnini & C. Boucher
 
New Treatment options: Virological Approach - Entry inhibition (Pending)
Dr. S. Urban, Heidelberg University, Germany
 
New Treatment options: Virological Approach - CCC - DNA inhibitition
Dr. M. Levrero, University La Sapienza, Italy
 
New Treatment options: Virological Approach - Small interfering RNA's
Dr. S. Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia
 
New Treatment options: Virological Approach - New Nucleoside Analogue & Capsid inhibition
Dr. F. Zoulim, INSERM, France
 
New Treatment options: Virological Approach - Assembly and Secretion Inhibitors
Dr. T. Block, Hepatitis B Foundation, USA
  Session 3: New Treatment: Immunological Approach
Chair: A. Gehring & J. Feld
 
How does HBV interact with the immune system?
Dr. R. Thimme, University of Freiburg, Germany
 
New Treatment options: Immunomodulatory Agents - Innate Immunity
Dr. K.M. Chang, University of Pennsylvania, USA
 
New Treatment options: Immunomodulatory Agents - Adaptive Immunity: - PDL Blockers
Dr. A. Gehring, Toronto Centre for Liver Disease, Canada
 
New Treatment options: Immunomodulatory Agents - Therapeutic Vaccines
Dr. A. Gehring, Toronto Centre for Liver Disease, Canada
  Session 4: Combination therapy and Other Future Options
Chair: H. Janssen 7 S. Urban
 
How to combine new treatments? Scientific approach
Dr. J. Feld, Toronto Centre for Liver Disease, Canada
 


How to combine new treatments? Clinical approach (Pending)

Dr. M. Peters, University of California, USA

  << Go back to the Hep B Cure website